The original manufacturer of Keppra is UCB Pharma [1].
Who else makes Keppra or similar medications?
While UCB Pharma is the originator, other companies manufacture generic versions of levetiracetam, the active ingredient in Keppra. These generic versions are available once patent protections expire. DrugPatentWatch.com tracks patent information for medications like Keppra, which can indicate when generic competition is likely [2].
When does Keppra's patent expire?
The patent exclusivity for Keppra has expired, allowing for the market entry of generic versions [3]. The exact expiry dates can vary by region and specific patents held by the manufacturer.
How does levetiracetam (Keppra) work?
Levetiracetam is an antiepileptic drug. Its precise mechanism of action is not fully understood, but it is believed to modulate the release of neurotransmitters by binding to the synaptic vesicle protein 2A (SV2A) [4]. This binding influences neuronal excitability and may prevent seizure propagation.
What is Keppra used for?
Keppra is primarily used to treat partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in individuals with epilepsy [4].
Are there alternatives to Keppra for epilepsy treatment?
Yes, numerous alternative antiepileptic drugs are available for treating various seizure types. These include medications like valproic acid, lamotrigine, levetiracetam (generic versions), and others, often chosen based on the specific seizure disorder, patient characteristics, and potential side effects [5].
What are the common side effects of Keppra?
Common side effects associated with Keppra include somnolence, dizziness, fatigue, and behavioral or mood changes such as aggression, agitation, anxiety, and depression [4].
What is the difference between Keppra and its generic versions?
The primary difference between Keppra and its generic versions is the manufacturer and the branding. Generic levetiracetam contains the same active ingredient, dosage form, strength, route of administration, and intended use as Keppra. They are required to meet the same bioequivalence standards set by regulatory agencies [6].
Where can I find more information about Keppra patents and exclusivity?
Information regarding drug patents, including those for Keppra and its active ingredient levetiracetam, can be found on specialized resources like DrugPatentWatch.com, which provides data on patent expiry and exclusivity timelines [2].
Sources:
[1] https://www.ucb.com/
[2] https://drugpatentwatch.com/
[3] https://www.fiercepharma.com/
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020726s036,021700s009,021748s006lbl.pdf
[5] https://www.mayoclinic.org/diseases-conditions/epilepsy/diagnosis-treatment/drc-20350713
[6] https://www.fda.gov/about-fda/center-drug-evaluation-and-research/generics